Literature DB >> 8692621

The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: an extended follow-up.

S Shinnar1, A T Berg, S L Moshe, C O'Dell, M Alemany, D Newstein, H Kang, E S Goldensohn, W A Hauser.   

Abstract

OBJECTIVE: To assess the long-term recurrence risks after a first unprovoked seizure in childhood.
METHODS: In a prospective study, 407 children who presented with a first unprovoked seizure were then followed for a mean of 6.3 years from the time of first seizure.
RESULTS: One hundred seventy-one children (42%) experienced subsequent seizures. The cumulative risk of seizure recurrence was 29%, 37%, 42%, and 44% at 1, 2, 5, and 8 years, respectively. The median time to recurrence was 5.7 months, with 53% of recurrences occurring within 6 months, 69% within 1 year, and 88% within 2 years. Only 5 recurrences (3%) occurred after 5 years. On multivariable analysis, risk factors for seizure recurrence included a remote symptomatic etiology, an abnormal electroencephalogram (EEG), a seizure occurring while asleep, a history of prior febrile seizures, and Todd's paresis. In cryptogenic cases, the risk factors were an abnormal EEG and an initial seizure during sleep. In remote symptomatic cases, risk factors were a history of prior febrile seizures and age of onset younger than 3 years. Risk factors for late recurrences (after 2 years) were etiology, an abnormal EEG, and prior febrile seizures in the overall group and an abnormal EEG in the cryptogenic group. These are similar to the risk factors for early recurrence.
CONCLUSIONS: The majority of children with a first unprovoked seizure will not have recurrences. Children with cryptogenic first seizures and a normal EEG whose initial seizure occurs while awake have a particularly favorable prognosis, with a 5-year recurrence risk of only 21%. Late recurrences do occur but are uncommon.

Entities:  

Mesh:

Year:  1996        PMID: 8692621

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  35 in total

1.  In search of epilepsy biomarkers in the immature brain: goals, challenges and strategies.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Outcome of convulsive status epilepticus: a review.

Authors:  Claire L Novorol; Richard F M Chin; Rod C Scott
Journal:  Arch Dis Child       Date:  2007-11       Impact factor: 3.791

3.  Findings from the FEBSTAT Study: Can Observations After a Provoked Seizure Occurrence Have Broad Implications for Epileptogenesis?

Authors:  Cynthia Harden
Journal:  Epilepsy Curr       Date:  2013-05       Impact factor: 7.500

4.  Can status epilepticus sometimes just be a long seizure?

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2013-05       Impact factor: 7.500

5.  An audit of first afebrile seizure management in an Irish tertiary pediatric setting.

Authors:  Michael Boyle; Joseph Chukwu; Mary Boyle; Ann Connolly; David Webb
Journal:  Eur J Pediatr       Date:  2013-11-01       Impact factor: 3.183

6.  Significance of the EEG after the first afebrile seizure.

Authors:  C P Panayiotopoulos
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

7.  Deficiency of laryngeal collagen type II in an infant with respiratory problems.

Authors:  K Frenzel; G Amann; B Lubec
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

8.  Status epilepticus in Indian children in a tertiary care center.

Authors:  Sheffali Gulati; Veena Kalra; M R Sridhar
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

Review 9.  Treatment strategies after a single seizure : rationale for immediate versus deferred treatment.

Authors:  Laura C Miller; Frank W Drislane
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Prognostic factors of status epilepticus in children.

Authors:  Du Cheol Kang; Young-Mock Lee; JoonSoo Lee; Heung Dong Kim; ChangJun Coe
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.